Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
S D BakerEric K Rowinsky

Abstract

To study the absolute bioavailability and pharmacokinetics of an oral solution of fluorouracil (5-FU) in patients treated with 776C85, an oral inactivator of dihydropyrimidine dehydrogenase (DPD), and to evaluate the feasibility of administering oral 5-FU and 776C85 on a multiple-daily dosing schedule. Twelve patients with refractory solid tumors were enrolled onto this three-period study. In periods 1 and 2, patients were randomly assigned to treatment with 5-FU 10 mg/m2 on day 2 given by either the oral or intravenous (IV) route with oral 776C85 3.7 mg/m2/d on days 1 and 2. In period 3, patients received escalating doses of 5-FU (10 to 25 mg/ m2/d) orally for 5 days (days 2 to 6) with 776C85 3.7 mg/m2/d orally (days 1 to 7) every 4 weeks. Pharmaco-kinetic studies were performed in periods 1 and 2, and after the fifth oral dose of 5-FU in period 3. Twelve patients completed the bioavailability and pharmacokinetic studies. Following oral 5-FU 10 mg/m2, the bioavailability was 122% +/- 40% (mean +/- SD), the terminal half-life (t1/2 beta) was 4.5 +/- 1.6 hours, the apparent volume of distribution (V beta) was 21.4 +/- 5.9 L/ m2, and the systemic clearance (Clsys) was 57.6 +/- 16.4 mL/min/m2. A correlation was observed between or...Continue Reading

Citations

May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J HarteP M Price
May 5, 2000·The Oncologist·S Sharma, L B Saltz
Oct 3, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J NemunaitisR Pazdur
Dec 7, 2000·Cancer Investigation·N L Lewis, N J Meropol
Jul 27, 2002·Adverse Drug Reactions and Toxicological Reviews·Sharon J GardinerBridget A Robinson
May 31, 2003·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Masanori TerashimaMitsukazu Gotoh
Feb 26, 2009·Expert Opinion on Drug Metabolism & Toxicology·Sridhar ManiSanjay Goel
Nov 10, 1998·Clinical and Experimental Pharmacology & Physiology·D M Thomas, J R Zalcberg
Aug 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S ManiJ Lokich
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F Y AhmedH L McLeod
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I E SmithC M Barton
Dec 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L GremC H Takimoto
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S D BakerE K Rowinsky
Dec 21, 2000·Current Oncology Reports·M E RoyceR Pazdur
Dec 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Michael, M M Doherty
Nov 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J PetersG Giaccone
Nov 30, 2010·Bioanalysis·John Chen, Michael Zhou
Feb 20, 2013·Clinical Pharmacokinetics·Frederik E StuurmanJan H M Schellens
Jun 27, 2017·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Kashappa Goud H Desai
Nov 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J Mayer
Oct 16, 1999·American Journal of Clinical Oncology·J S Macdonald
Oct 29, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·F G JansmanJ R Brouwers
Feb 10, 2006·Cancer Investigation·Anthony B El-Khoueiry, Heinz-Josef Lenz
May 14, 2008·World Journal of Gastroenterology : WJG·Toru Ishikawa
Nov 4, 2000·Expert Opinion on Investigational Drugs·R L Schilsky, H L Kindler
Jan 5, 2001·Expert Opinion on Investigational Drugs·R Pazdur, M E Royce
Feb 24, 2001·The Annals of Pharmacotherapy·J G Kuhn
Sep 14, 2006·Pharmacological Reviews·Sharon J Gardiner, Evan J Begg
Nov 20, 2004·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Toshiaki SaekTetsuo Taguchi
Oct 18, 2001·Anti-cancer Drugs·P G Johnston, S Kaye
Mar 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alex A AdjeiCharles Erlichman
Aug 7, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Quincy Siu-Chung ChuEric K Rowinsky
Nov 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy J HobdayRichard M Goldberg
Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·N J Meropol

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.